Custom cancer vaccine fights deadly brain tumor in early trial
NCT ID NCT05743595
Summary
This early-stage study is testing whether a personalized DNA vaccine, created from a patient's own tumor, can be safely combined with an immunotherapy drug (retifanlimab) to treat newly diagnosed glioblastoma. The goal is to see if this combination can train the immune system to recognize and attack the cancer cells. Researchers will monitor 27 patients for safety and measure how well their immune systems respond to the vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNMETHYLATED GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.